Learning Library Video

PT-141 for Low Desire: Benefits, Limits and Risks

Back to VideosHub ResourcesOpen Source
Source domain: www.youtube.com
Video from Travis Woodley

Short, 2:02. Published November 9, 2026. Travis Woodley, MSN, RN, CRNP. Series: Peptides.

PT-141 (bremelanotide) was studied in more than 1,200 premenopausal women with acquired, generalized low sexual desire causing distress. About 25% versus 17% on placebo reached at least a 1.2-point improvement on a desire scale: roughly eight additional women per 100 reached that specific threshold, not a universal response rate.

The approved use is acquired, generalized HSDD in premenopausal women. Other causes of low desire need evaluation. Nausea affected about 40% of treated participants. Blood pressure can rise temporarily; uncontrolled hypertension or known cardiovascular disease are contraindications. Slower stomach emptying can affect oral medicines, notably oral naltrexone.

Educational only, not personal medical advice. Discuss treatment and supplement decisions with your qualified clinician.